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We have tested a multiplex polymerase chain reaction (PCR) human papillomavirus
(HPV) genotyping assay to fill the need for rapid and low‐cost HPV detection in Sub‐
Saharan Africa. This method allows high throughput genotyping and simultaneous
detection of 14 high‐risk and two low‐risk HPV types, by PCR amplification of HPV
DNAs in a single reaction tube. In this study, we describe stepwise experiments to
validate the multiplex HPV PCR assay for determination of HPV genotypes from 104
cervical brush samples from Tanzanian women. Assay performance was evaluated by
determination of intra‐laboratory reproducibility, sensitivity, and specificity. Further
performance was assessed by comparison with the widely accepted and validated HPV
My09/My11 amplification and hybridization assay. Statistics; the Cohen kappa (κ) and
McNemar P values were used to analyze interobserver and intermethod agreement.
Overall concordance between the multiplex and line blot hybridization assays was 99%
(per sample) with a κ value equal to 0.95; and 96.49% (per detection event) with a κ
value of 0.92. Interobserver reproducibility of the assay per sample was 95.76% with κ
of 0.91. These results demonstrate that the multiplex HPV PCR assay has high analytical
sensitivity and specificity in detecting as many as 16 different HPV genotypes and that
its simplicity and low cost makes it well suited for sub‐Saharan Africa.
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1 | INTRODUCTION
Cervical cancer is the fourth most common cancer in women
worldwide (528 000 new cases), and the second most common
cancer in developing countries (445 000 new cases) in 2012.1 The
disease burden is greatest among women from low‐ and middle‐
income countries (LMIC) and with limited medical service re-
sources.1,2 In Sub‐Saharan Africa, the age‐standardized rate for
cervical cancer is approximately 35 per 100 000 women.1 Due to lack
of cervical cancer screening services, African women are more likely
to present with late‐stage cancers, thus causing significant treatment
expense to families and governments.3 Human papillomavirus (HPV)
is one of the most common sexually transmitted infections (STIs) in
the world. A majority of epidemiological studies have established that
HPV is the primary cause of cervical cancer and genital warts.4-6
Persistent HPV infection with additional exposure to tobacco, oral
contraceptives and parity,7 lead to an increased risk of cervical
dysplasia, accumulation of mutations, and integration of HPV
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genomes into the host genome; which finally leads to the progression
toward high‐grade dysplasia and cervical cancer.
Current approaches to reduce the incidence of cervical cancer rely
upon cervical cancer screening methods and prophylactic HPV
vaccines.8-12 The screening methods include either visual inspection,
cytology evaluation, and HPV tests. The visual inspection test consists
of the naked eye inspection of the cervix after the application of 3% to
5% acetic acid (VIA) or the Lugol iodine (VILI) using a cotton swab. The
visible changes in tissue pigmentation after solution application are
classified as positive (lesion) or negative (normal) results. The
Papanicolaou (Pap) test detects precancerous lesions at the cellular
level by identification of abnormal or large nuclei. In this method, a small
sample of cells is collected from the cervix and examined under an
optical microscope by a pathologist. However, HPV DNA testing is
considered the most objective, sensitive, and highly reproducible
cervical screening approach to date. These assays test for the presence
of DNA or RNA from high‐risk (HR) HPV types in cervical cells and are
used in conjunction with cervical screening particularly when the Pap or
VIA results are inconclusive.13 HPV testing is still considered a
cotest,14-16 yet has been used as primary cervical screening in some
European countries.17 Some limitations in using HPV testing in
developing countries are the cost, the laboratory infrastructure needed,
and the need for trained laboratory technicians. There are several HPV
testing methods available. Multiplex HPV PCR is a common method
which relies on simultaneous amplification of target DNAs of different
molecular weights, each corresponding to a different HPV genotype.
In this study, results from an HPV multiplex PCR genotyping
assay were compared with that of the My9/My11 hybridization assay
as the “gold standard.” In low‐income countries, often cost and
availability make more sophisticated HPV genotyping assays18
unobtainable. In addition, although there are several HPV test kits
available in the market, their reliability and validity still need to be
evaluated.19,20 HR HPVs are associated with cervical cancer whereas
the LR HPV types such as 6 and 11 are associated with benign genital
warts, hence both are included in the multiplex PCR assay.1,21 In this
study we adapted and validated a multiplex HPV PCR assay which
detects 14 HR HPV genotypes (16, 18, 30, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, and 66); and two low‐risk (LR) HPV genotypes (6 and 11)
in a single reaction.22 Our performance analysis showed that the
HPV multiplex PCR genotyping assay is a reliable low‐cost
alternative to commercial methods.
2 | MATERIALS AND METHODS
2.1 | Study population and specimen collection
The study protocol was reviewed and approved by the Institutional
Review Boards of Ocean Road Cancer Institute (ORCI), Dar es Salaam,
Tanzania and the University of Nebraska‐Lincoln. The participant
women were recruited from ORCI, Bagamoyo and Chalinze screening
clinics, and informed consent was obtained from the women before
sample collection. Women had a gynecological examination, including
visual inspection with acetic acid and a conventional Pap test. Pap
smear collection was performed using the concave end of an Ayer’s
spatula, samples were evenly spread on a glass slide and sprayed with
fixative. Pap smear results were determined by three blinded cytologists
according to Bethesda classification system 2001.23 For HPV DNA
genotyping, cervical cells were collected from the opening of the cervix
using a cytobrush. Each brush was put into a cryotube and stored at 4°C
until DNA extraction.
2.2 | DNA extraction of cervical samples
Cervical DNA was extracted from cytobrushes with 200 µL lysate
solution according to the Qiagen DNeasy Blood & Tissue Kit (Qiagen
Inc, Valencia, CA; cat no. 69506). The DNA concentrations of the
samples was determined using a NanoDrop Spectrophotometer.
Cervical DNA samples were stored at −20°C until PCR analysis.
2.3 | Multiplex PCR assay
Sixteen HPV genotypes (6, 11, 16, 18, 30, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, and 66) were obtained from Karolinska Institute
(International HPV Reference Center, Sweden). These plasmids were
used as controls and test amplicons in the analytical experiments.
The cloned PGEMT was obtained from Promega (Madison, WI). The
aminolevulinate synthase 1 (ALAS1) gene was cloned into the
PGEMT vector and the construct was used in the analytical,
sensitivity, and specificity experiments. All plasmids were confirmed
by restriction digest before HPV genotyping experiments. PCRs were
performed using a multiplex PCR kit (Qiagen Inc; Redwood City, CA),
according to manufacturer’s instructions. A previously developed
protocol, with minor modifications, was followed.22 At least 50 ng of
DNA sample solution (HPV DNA plasmid or clinical sample) was used
as a template for PCR amplification. Samples were incubated at 95°C
for 15minutes, followed by 40 cycles of denaturation at 94°C
(30 seconds), annealing at 70°C (90 seconds), and extension at 72°C
(60 seconds). PCR products were analyzed on a 6% polyacrylamide
gel electrophoresis (PAGE) in 1XTBE and stained with ethidium
bromide. Gel images were captured with a ChemiDoc MP Imaging
System (Bio‐Rad; Hercules, CA). A positive genotyping result was
called if a clear band was visualized on the gel. All HPV genotypes
were detected by a single band except for HPV types 16 and 58,
which were detected by two separate bands.22
End‐point detection limits of HPV genotype‐specific PCR was
achieved by serial dilutions of each respective HPV template DNA,
plus 1000 ng of Salmon sperm DNA as a carrier in each reaction
tube. This experiment was used to optimize each HPV genotype
primer set. End‐point detection limits were performed for individual
or multiple HPV genotypes present in a single reaction tube.
Reproducibility experiments were repeated twice within 2 to 3
weeks, by two blinded observers who read identical gel images. For
the purposes of the analytical performance comparisons, and for
training of Tanzanian lab personnel, the described genotyping
experiments were done in the United States.
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2.4 | HPV hybridization method
PCR was performed using biotin‐labeled MY09/MY11 consensus HPV
L1 primers, in addition to biotin‐labeled human β‐globin primers, which
were used as an indicator of DNA quality as previously described.24
About 50 ng of DNA was added to each 100 µL PCR reaction and
subjected to 40 amplification cycles. One hundred and three samples
were interrogated by this method. Products were first hybridized
against the cellular control DNA, β‐globin, then against membrane
bound arrays of HPV standard DNAs. Standard DNAs included 38
different HPV types: 6/11, 16, 18, 26/69, 30, 31, 32/42, 33, 34, 35, 39,
45, 51, 52, 53, 54, 56, 57/2/27, 58, 59, 61, 62, 66, 67, 68, 70, 71, 72, 73,
81, 82, 83, 84, 85, 86/87, 90/106, 97, and 102/89. There were two
separate mixtures, mix‐1 contained 7, 13, 40, 43, 44, 55, 74, and 91,
while mix‐2 contained 3, 10, 28, 29, 77, 78, and 94. Negative specimens
for β‐globin gene amplification were excluded from the analysis. PCR
results were recorded on a 0 to 5 scale based on the signal intensity of
dot‐blots. For comparison purposes, a sample genotyped by hybridiza-
tion method was considered positive only if one or more of the sixteen
HPV genotypes present in the multiplex HPV PCR assay was detected;
otherwise the sample was considered negative.
2.5 | Statistical analyses
All statistical analyses were carried out using SAS software, version
9.4 (Cary, NC) and Excel 2016 (Microsoft, Seattle, WA). For purposes
of the assay performance analyses, we chose a sample size of 104.
This initial sample size was based on resource practicality in the
absence of reliable data on the expected performance of both assays.
Agreement assessment, between methods (multiplex HPV PCR and
hybridization) and observers, was assessed by Cohen’s kappa test,
which is a standard statistical tool for assay performance comparison.
The Cohen kappa coefficient (κ) varies from 0 to 1, where 0 to 0.20
indicates slight agreement, 0.21 to 0.40 fair agreement, 0.41 to 0.60
moderate agreement, 0.61 to 0.80 substantial agreement and 0.81 to
1 near perfect agreement. The Cohen kappa tests were performed
per sample or per event, where an event is considered to be a specific
HPV genotyping call, including a negative call. Contingency tables
were used to calculate sensitivity and specificity values with 95%
confidence intervals (CIs). The McNemar statistical test is a second
tool for assessment of different assay methods. A McNemar test with
a P value of 0.05 is considered significant, however when there is
perfect agreement, and there are zero discordances, then a P value of
1 is still considered significant.25 Clinical sensitivity was calculated as
the proportion of women with high‐grade lesions (ASC‐H and HSIL)
tested as positive by mPCR or the hybridization method. Clinical
specificity was calculated as the proportion of women who tested
negative among those without high‐grade lesions (NILM‐LSIL).
3 | RESULTS
The multiplex HPV PCR assay utilizes amplified products from 16
different HPV genotypes which map to different regions in the linear
F IGURE 1 Schematic diagram of PCR products mapped on HPV genome. Each of the 16 PCR products of the different HPV genotypes are
shown mapped to different open‐reading frames on the linear representation of HPV genome. The black arrows indicate the size of each
amplicon. HPV, human papillomavirus; PCR, polymerase chain reaction
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HPV genome (Figure 1). HPV16 has two PCR products, a lower
HPV16 band (L) (217 bp), and an upper HPV16 band (U) (397 bp). The
analytical sensitivity of detection of each of the 16 different HPV
genotypes was analyzed by PAGE, as shown in Figure 2. The end‐
point detection limit of HPV genotypes 6, 11, 16(L), 18, 30, 31, 33,
39, 45 and 58 ranged from 1 to 10 copies; and 10 to 100 copies for
HPV genotypes 16(U), 35, 52, 56, 59, and 66. The number of copies
per reaction determined by the multiplex HPV PCR assay were
comparable to that obtained from real‐time PCR and capillary
electrophoresis (CE) methods and gel electrophoresis (Table 1). Real‐
time PCR had the lowest detection limits when compared with the
other two methods. Overall, the end‐point detection limits obtained
with the multiplex assay were comparable to the ones obtained by
CE. The end‐point detection limit assays of the multiplex PCR assay
containing six different HPV genotypes (6, 16, 31, 33, and 52) is
shown in Figure 3. This figure demonstrates that the number of
copies detected when using the mixture were similar as those
detected for their respective individual HPV genotypes; 1 to 10
copies for 6, 16(L), 31, and 33 and 10 to 100 copies for HPV
genotypes 16(U) and 52 (Figure 2). In addition, these results suggest
that the multiplex HPV PCR assay possesses high specificity in
detecting each of the six HPV genotypes with no exhaustion of PCR
reagents.
The agreement charts for comparison between observer calls
using the Multiplex HPV PCR assay are shown in Figure 4. For the
“per sample” comparison (Figure 4A), the chart shows an almost
perfect agreement (dark gray shading), with only a small partial
agreement region (light gray shading) for the negative and positive
results. The proportion of agreement “per sample” analysis was 99%
(103/104 samples), and the Cohen kappa coefficient was 0.978 (95%
CI, 0.934‐1.000). The McNemar P value was 0.3173. Regarding the
“per event” (per genotype) comparison, the proportion of agreement
was 97.4% (114 of 117 events), with a κ coefficient value of 0.946
(95% CI, 0.885‐1.000) (Figure 4B). The corresponding McNemar
P value was 0.5637. The exact agreement regions, shown in Figure
4B, are slightly smaller than those in the “per sample” graph (Figure
4A) due to an increased number of “events” counted. These results
indicate that there is excellent agreement between the detection
methods. The results of this comparison is summarized in Table 2.
Figure 5 shows the comparison of detection of 103 cervical
samples between multiplex HPV PCR (filled circles) and hybridization
(open triangles) methods. In this analysis, one of the samples was not
considered because there was a disagreement between observers’
calls for the multiplex assay. Our results showed that 4 out of 103
samples were discordant. Specifically, two cervical samples, which
were HPV negative by the hybridization method, were found to have
HPV types 33 and 66 by the multiplex assay. These corresponded to
samples number 5 and 73, respectively. Furthermore, two additional
HPV genotypes were detected in samples number 20 and 54, which
were not detected by the hybridization method: HPV types 11, 18,
and 66 (mPCR); and HPV 33 and 66 (mPCR), respectively (Figure 5).
In essence, these results suggest the HPV mPCR method has superior
sensitivity.
Figure 6 shows the agreement charts for the comparison between
the two genotyping detection methods. The proportion of agreement
per sample was 98% (101 of 103 samples), and the Cohen kappa
coefficient obtained was 0.955 (95% CI, 0.891‐1.000) (Figure 6A). The
corresponding McNemar score was P = 0.3173. The proportion of
agreement of the per‐event analysis was 96.5% (109 of 113 events),
while the κ coefficient was 0.923 (95% CI, 0.849‐0.997) (Figure 6B).
The McNemar score was P = 0.5637. Overall, results in both cases
indicate almost perfect agreement between the Multiplex HPV PCR
and HPV hybridization assays. Each of the McNemar scores is
significant up to a value of 1. These results indicate excellent
agreement between the methods. The results of this comparison is
summarized in Table 2.
Of the 104 cervical samples used, 12.50% were negative for
intraepithelial lesion or malignancy (NILM) while the remaining had
atypical squamous cells of higher pathological categories (ASCUS‐
HSIL). Thirty‐three samples out of 104 samples tested positive by
multiplex HPV PCR assay, none of the samples were excluded from
the analysis as all samples had sufficient human DNA, as indicated by
the internal control. In testing the reproducibility of the multiplex
F IGURE 2 Determination of the end‐point detection limit of each
of the 16 HPV genotypes using the multiplex PCR assay. Ten‐fold
serial dilutions of the internal control (IC: aminolevulinate synthase
1, ALAS1) or each of the HPV DNAs were subjected to amplification.
HPV genotypes −6, 11, 16(L), 18, 30, 31, 33, 39, 45, and 58 were
detected at 1 to 10 copies per reaction, whereas HPV genotypes −16
(U), 35, 52, 56, 59, and 66 were detected at 10 to 100 copies per
reaction. The dilutions of PCR templates is indicated above each lane
(108 to 1 viral copy per reaction). Neg, indicates a reaction without
HPV DNA added. ALAS1, aminolevulinate synthase 1; HPV, human
papillomavirus; PCR, polymerase chain reaction
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PCR assay, the samples were retested 2 to 3 weeks from the initial
test, gel analyses for genotype calls were analyzed by two
independent observers.
The analytical sensitivity and specificity of the multiplex HPV
PCR assay were 100% and 94.26%, respectively. The clinical
sensitivity is defined as the ability of the test to correctly identify
those patients with disease, in this case the patients who had pap
smear results of ASC‐H to HSIL. While the clinical specificity refers to
the ability of the test to correctly identify those patients without the
disease (LSIL‐NILM).35 The clinical sensitivity and specificity of the
multiplex HPV PCR and Line Blot hybridization using the Bethesda
classification system 2001 were comparable.
Table 3 shows the HPV genotyping results of both methods
according to the pap smears results. For the case of normal pathology
(NILM) both methods detected the same number of positive and
negative results. Regarding the abnormal pathology (ASCUS‐HSIL)
TABLE 1 Comparison of end‐point detection limits obtained by real‐time PCR, capillary electrophoresis, and gel electrophoresis
Detection limit (no. of molecules/reaction)
HPV type Amplicon size, bp Amplified region Real‐time PCR Capillary electrophoresis Multiplex HPV PCR
6 263 E6 1 10‐100 1‐10
11 472 E7 1 1‐10 1‐10
16L 217 L2 1 1‐10 1‐10
16U 397 E1 1 10‐100 10‐100
18 187 E1 1 1‐10 1‐10
30 249 L2 1 1‐10 1‐10
31 360 L2 1 1‐10 1‐10
33 139 E1 1 1 1‐10
35 434 E6‐E7‐E1 1 10‐100 10‐100
39 229 E2 1 1‐10 1‐10
45 205 L2 1 1‐10 1‐10
51 299 E7‐E1 1 1‐10 1‐10
52 517 E5‐L2 1 1‐10 10‐100
56 330 LCR 1 10‐100 10‐100
58 128 E2 1 1‐10 1‐10
59 169 E6‐E7 1 10‐100 10‐100
66 277 L1‐LCR 1 10‐100 10‐100
IC 100 ALAS1 1 1 1‐10
Abbreviations: ALAS1, aminolevulinate synthase 1; HPV, human papilloma virus; PCR, polymerase chain reaction.
F IGURE 3 The end‐point detection limit of multiple HPV templates using the multiplex PCR assay. HPV genotypes: 6, 16, 31, 33, 52, and 56
were diluted by 10‐fold serial dilution and subjected to multiplex PCR. The relative detection limit is indicated by the copy number per reaction
above each lane (106 to 1 copies per reaction). HPV, human papilloma virus; Neg, negative control (without HPV DNA); Marker, 1‐kb DNA
marker; PCR, polymerase chain reaction
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classification, it is shown that the mPCR assay is more sensitive than
the hybridization assay, since the HPV mPCR assay detected two
more positive samples than the hybridization assay.
4 | DISCUSSION
The main goal of this study was to validate the analytical detection of
HPV genotypes by the multiplex HPV PCR assay comparison with the
clinically validated, WHO‐approved, HPV (My09/My11) hybridiza-
tion method. Overall, this comparison is highly concordant, consis-
tent, and reproducible. We chose to calculate the efficiency of HPV
genotype detection per sample as well as per event (per genotype),
so that we could determine if differing multiplicities of HPVs affected
detection efficiency. The assay demonstrated high analytical sensi-
tivity in detecting HPV DNA at very low copy number (between 10
and 100 copies per cell), which is crucial to studying the natural
history of HPV pathogenesis and disease diagnosis.26,27 The down-
stream analyses using either PAGE or CE gives the researcher
choices depending on resource availability, while still using the same
simple PCR method.
Agreement between observers was 97.4% with a κ coefficient value
of 0.946 (113 of 118 events), and 99% with κ coefficient equal to 0.978
(103 of 104 samples), with a McNemar score of P=0.3173, signifying
almost perfect agreement. As a matter of routine, we believe that it is
more reliable to have two independent observers do genotype calls.
Table 2 shows the results of all performance assays. The HPV mPCR
assay offers high reliability for detection of HPV genotypes present in a
single reaction, without exhaustion of PCR reagents (shown in Table 1).
This result shows that the assay can be reliable when simultaneous
detection of multiple HPV genotypes is required.28 Several studies
suggest that infection of multiple HPV genotypes in the cervical
epithelium is associated with development of cervical neoplasia.29,30 Like
most of the HPV DNA amplification tests, mPCR showed high analytical
sensitivity. Because of the extreme sensitivity of the assay, we prefer to
premix reagents in PCR tubes under in a PCR clean room under an
isolation hood. We clean all work surfaces, pipettes and gloves with 10%
bleach before mixing reagents to avoid cross contamination.
F IGURE 4 Agreement chart for intra‐observer calls by multiplex HPV PCR assay. A, Agreement between observers per sample. B,
Agreement between observers per event. Shaded squares indicate exact agreement (dark gray), and partial agreement (light gray). HPV, human
papilloma virus; PCR, polymerase chain reaction
TABLE 2 Summary of statistical tests of the HPV mPCR assay performance in comparison to the My9/My11 HPV hybridization assay
Percent agreement Cohen kappa McNemar Sensitivity Specificity
mPCR vs My9/My11 blot
Per sample 98% 0.955 P = 0.3173 100% 94%
Per event (genotype) 96.50% 0.923 P = 0.0455
mPCR Intraobserver comparison
per sample 99% 0.978 P = 0.3173
Per event (genotype) 97.40% 0.946 P = 0.5637
Abbreviations: HPV, human papilloma virus; PCR, polymerase chain reaction.
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Comparing the HPV mPCR assay with the hybridization method
demonstrates almost perfect agreement for the sixteen HPV
genotypes tested (see Table 2). The selection of HR HPV genotypes
16, 51, 35, and 18 in this assay makes it useful in Sub‐Saharan African
countries,31 where these genotypes are highly prevalent. Since the
multiplex PCR assay detects most of the relevant HR‐HPVs as well as
the LR‐HPV which cause condylomas (HPV 6 and 11), it provides the
most disease‐relevant information. The multiplex HPV PCR proved
an efficient use of resources since it has a reagent cost of only $3 per
sample, including US to Tanzanian shipping costs for 1000 premixed
reactions, the final reagent cost rises to about $3.10 per sample.
Commercial HPV genotyping kits often require expensive assay
detection equipment such as real‐time PCR machines or proprietary
detectors. For example, the Panatyper real‐time PCR kit (Panagene;
Deajeon, South Korea), which detects 20 HR‐HPVs, costs approxi-
mately $33 per sample. But this also requires a four‐color real‐time
PCR machine. A similar real‐time PCR kit (Biotivate, Cincinnati, OH)
to detect 21 HPVs, costs about $28 per sample. The more popular
HPV linear array kits cost more than $40 per sample to run. Such
assays are too expensive for sustainable clinical use in Sub‐Saharan
Africa. The advantages of the HPV multiplex PCR assay are that it
requires minimal reagents and is performed in a single reaction tube.
From PCR reaction to genotype determination takes about 4 hours.
We found that the HPV multiplex PCR assay had the ability to detect
HPV16 in African samples, despite the fact that there are known to be
Africa‐specific HPV16 variants from the region.32 Some further
optimization of this assay for African‐specific variants may improve
detection of HPV16 and perhaps other genotypes. Because of the
sensitivity, this assay may also be useful to assess the role of HPV in
Adenocarcinomas. We did a small‐scale analysis of the HPV multiplex
assay for its ability to predict clinical disease determined by pap smear.
Clearly, a thorough clinical analysis would be needed with a much larger
sample size to assess the clinical value of the assay.33 High sensitivity and
specificity in clinical samples would suggest that the assay has potential
use particularly in low‐resource clinical settings. Cervical cancer is highest
in low income countries, thus, simple low‐cost solutions to assess HPV
related disease are essential.1 The WHO has now suggested that HR
HPV DNA testing should be prioritized over VIA. This will require well‐
validated and inexpensive HPV DNA detection assays.34 The HPV
multiplex assay described here would be a good candidate for clinical use
in Sub‐Saharan Africa.
F IGURE 5 Comparison of the HPV genotype detection efficiency
between multiplex HPV PCR and HPV hybridization methods. The
different HPV genotypes detected are represented as filled circles
(multiplex PCR) and open triangles (hybridization method). The
results from 103 samples were compared. HPV negative results are
also shown in the plot. HPV, human papilloma virus;
PCR, polymerase chain reaction
F IGURE 6 Agreement charts for comparison of the HPV genotyping detection methods. A, Agreement chart of detection methods per
sample. B, Agreement chart of detection methods per event. Shaded squares indicate exact agreement (dark gray) and partial agreement (light
gray). HPV, human papilloma virus; PCR, polymerase chain reaction
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